|
Xenazine (Tetrabenazine Tablets)
 This product requires a valid prescription
| |
|
Type |
Strength |
|
Quantity |
|
Price (USD) |
|
|
| |
|
Nitoman (Tetrabenazine) is used in the treatment of hyperkinetic movement disorders such as Huntington's chorea, Hemiballismus, Senile Chorea, Tic and Gille's de la Tourette Syndrome and Tardive Dyskinesia. Nitoman (Tetrabenazine) is not indicated for the treatment of levodopa-induced dyskinetic/choreiform movements (see Warnings). Nitoman (Tetrabenazine)should only be used by (or in consultation with) physicians who are experienced in the treatment of hyperkinetic movement disorders. Nitoman (Tetrabenazine) is contraindicated in patients with a current episode or a history of clinical depression. Nitoman (Tetrabenazine)should not be administered together with a MAO inhibitor. At least 14 days should elapse between the discontinuation of an MAO inhibitor and initiation of treatment with Nitoman (Tetrabenazine), as well as between the discontinuation of Nitoman (Tetrabenazine)and the initiation of treatment with an MAO inhibitor. The central effects of Nitoman (Tetrabenazine)closely resemble those of reserpine, but it differs from the latter in having less peripheral activity and in being much shorter acting. Nitoman (Tetrabenazine)also has dopamine antagonistic effects, such as displacing -spiperone from striatal binding sites in vitro, and blocking dopaminergic inhibition of prolactin release in vitro and in vivo. Nitoman (Tetrabenazine) may cause drowsiness and orthostatic hypotension. Therefore caution is recommended when driving, operating machinery, or performing other skilled tasks until the effects of Nitoman (Tetrabenazine) are known. There is a potential for severe manifestations of dopamine deficiency, when administering Nitoman (Tetrabenazine) concomitantly with neuroleptic agents (e.g., haloperidol, chlorpromazine, metoclopramide, etc.). The most commonly observed Nitoman side effects include: signs and symptoms of Parkinsonism; drowsiness, fatigue, weakness; depression; anxiety, nervousness; insomnia; restlessness, akathisia; drooling; irritability, agitation; nausea, vomiting, epigastric pain; confusion, disorientation; hypotension; dizziness.
Depression: Nitoman (Tetrabenazine) may cause depression. Recognition of depression may be difficult because this condition may often be disguised by somatic complaints. Nitoman (Tetrabenazine) should be stopped immediately at the first signs or symptoms of depression. The depression can be profound, and the possibility of suicide should be kept in mind until the depression clears. There is no information on the safety or efficacy of antidepressant drug treatment in Nitoman (Tetrabenazine)-induced depression.
Symptoms of Nitoman (Tetrabenazine) overdosage may include drowsiness, sweating, hypotension and hypothermia.
If there is no improvement at the maximal tolerated dose of Nitoman in 7 days, it is unlikely that Nitoman (Tetrabenazine) will be of benefit to the patient, either by increasing the dose or by extending the duration of treatment.
|
|
|
|
